Why the study?
While viral load quantification is standard in transplant recipients, persistent challenges in standardization limit the clinical utility and full impact of testing on management decisions.
Persistent interassay variability in transplant viral load testing hinders the establishment of consensus therapeutic thresholds and clinical guidelines.
Variability precludes reliable therapeutic thresholds in transplant monitoring; leaves open the need for standardized, commutable assays.
While quantification of viruses that cause important infections in transplant recipients has been the standard of care for years, important challenges related to standardization remain. The issues are wide ranging, and until they are adequately addressed, the full impact of viral load testing regarding clinical management decisions will not be realized. This review focuses on a broad array of problems, including the lack of available FDA-approved/cleared tests, limited uptake of international standards, accurate quantification of secondary standards, specific assay characteristics, and commutability. Though some of these topics are nuanced, taken together they greatly influence the clinical utility of testing. For example, it has not been possible to define thresholds that predict the risk of developing disease and determine significant changes in serial viral load values for a given patient. Moreover, the utility of international guidelines may be limited due to the lack of a standardized assay. By summarizing the issues, the hope is that commercial companies, regulatory agencies, and professional societies can come together to advance the field and solve these problems.
No takes yet. Share an insight, caveat, or question.
Hayden et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: